|This Slide: #90 of 100|
Slide #90. Imprimis Pharmaceuticals, Inc. — Intellectual Property Assets from Buderer Drug Company
Imprimis Pharmaceuticals, Inc. (IMMY)
Intellectual Property Assets from Buderer Drug Company
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug Company. The acquisition allows Imprimis to pursue the commercial development of these proprietary innovations and also provides Imprimis with a right of first refusal on additional Buderer Drug Company intellectual property and drug development opportunities.
Imprimis Pharmaceuticals is an ophthalmology-focused pharmaceutical company focused on the development, production and sale of medications. Co. operates its business through several subsidiaries: ImprimisRx, an ophthalmology focused compounding business; Park Compounding, a custom compounding business focused on patient specific orders; and Surface Pharmaceuticals, Inc., an ocular surface disease-focused 505(b)(2) specialty pharmaceutical subsidiary.
Open the IMMY Page at The Online Investor »
Free IMMY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Strong Buy (4.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite